Clinical trial · Observational
18F-FSPG PET/CT Imaging in Patients With Cancers
(4S)-4-(3-[18F]Fluoropropyl)-L-glutamate Radiotracer (FSPG) PET/CT for Imaging xC- Transporter Activity in Cancers
NCT03144622CI-TRIAL-00041347unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to compare the diagnostic performance of 18F-FDG and 18F-FSPG PET/CT in lung, breast, and abdominal cancers before undergoing therapy. In addition, the role of 18F-FSPG PET/CT in evaluating therapy response and prognosis will also be evaluated.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abdominal Cancer | Malignant Abdominal Neoplasm | ALIAS | 0.90 |
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Pulmonary Cancer | Lung Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Staging ability of 18F-FSPG PET/CT
- timeFrame
- 3 years
- description
- Sensitivity, specificity, diagnostic accuracy of 18F-FSPG and 18F-FDG PET/CT will be compared according to patient-based and lesion-based analysis using paired t-test or Krusal-Wallis test.
- measure
- Ability of 18F-FSPG PET/CT in therapy response evaluation and prognosis prediction
- timeFrame
- 3 years
- description
- Comparison between 18F-FSPG and 18F-FDG PET/CT will be done using both qualitative and quantitative measures
Secondary outcomes (2)
- measure
- Uptake of 18F-FSPG
- timeFrame
- 3 years
- description
- Standardised uptake values (SUV) will be compared between 18F-FSPG and 18F-FDG
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients are given the opportunity to participate in the study if 1. Age ≥ 20 years old. 2. Confirmed diagnosis of primary cancer of the following: NSCLC, breast or abdominal cancers 3. ECOG performance status 0 to 2. 4. Life expectancy \> 3 months. 5. Consent to perform additional 18F-FSPG and 18F-FDG PET prior to therapy. 6. Sexually active subjects agree to use condoms and/or their partners of reproductive potential to use a method of effective birth control during imaging period of 2 weeks. Exclusion Criteria: * Patients with any of the following conditions will be excluded 1. Had received previous treatment (excluding neoadjuvant therapy). 2. Pregnant or lactating women. 3. Known malignancy in other organs. 4. Evaluated by primary care physician as unsuitable. 5. Known hypersensitivity to the study drug.
References
Publications (0)
Data not yet available
No reference posted for this study.